Concern about possible cardiovascular problems associated with Vioxx, however, soon arose.
That means Vioxx results cannot automatically be extended to Celebrex and Bextra, which are in the Cox-2 classification with Vioxx but are not identical to it.
By contrast, Vioxx made $2.5 billion for Merck last year.
Celebrex and Vioxx have become household names in recent years.
Although that study's findings did not cause Vioxx to be withdrawn, Miller and Lopez-Mendez said the results put Vioxx lower on their list for prescribing.
Vioxx was easier on the stomach than aspirin, but it cost more.
The last days of Vioxx began with FedEx deliveries on Sept. 14.
